Dual-targeted nanomedicines for enhanced tumor treatment

Yaqin Zhu, Jan Feijen*, Zhiyuan Zhong*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

47 Citations (Scopus)

Abstract

Based on the overexpression of specific receptors on tumor cells, active targeting nanomedicines have been developed with the ability to efficiently deliver imaging agents in the tumor area or anticancer drugs into tumor cells via receptor-mediated endocytosis. Nevertheless, the efficacy of single-ligand nanomedicines is still limited due to the complexity of the tumor microenvironment. In recent years, dual-ligand nanomedicines have attracted a lot of interest, because these nanomedicines endowed with versatile functions, have the potential to improve the efficacy of tumor-targeted delivery. In this review, an overview of various dual-ligand nanomedicines for tumor targeted therapy will be presented, the role of cell penetrating peptides in combination with targeting ligands will be discussed and factors that affect the targeting efficacy of dual-ligand nanomedicines will be evaluated.

Original languageEnglish
Pages (from-to)65-85
Number of pages21
JournalNano today
Volume18
DOIs
Publication statusPublished - Feb 2018

Keywords

  • UT-Hybrid-D
  • Dual-ligand
  • Nanomedicine
  • Receptor-mediated endocytosis
  • Targeting efficacy
  • Tumor therapy
  • Tumor-targeted delivery
  • Cell-penetrating peptides

Fingerprint

Dive into the research topics of 'Dual-targeted nanomedicines for enhanced tumor treatment'. Together they form a unique fingerprint.

Cite this